BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGuangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177) ,a commercial-stage biopharmaceutical company, today announced that dosing hasbegun in a Phase I clinical study to compare the pharmacokinetics and safety ofBAT2606, a proposed biosimilar of Nucala ® (mepolizumab), toUS-sourc...
Guangzhou,China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), acommercial-stage biopharmaceutical company, announced today the details of its poster presentation at the VaccinesSummit 2022, being held fromOctober 11-13inWashingtonD.C. Bio-Thera will present research andpreclinical resul...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company,announced today that enrollment for the Phase I clinical study of BAT2022 hasbeen completed, showing that BAT2022 is well-tolerated and there were no DLTobserved up to the dose of ...